Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

被引：0
|
作者：
Ash Bullement
Samuel Thomas McMordie
Anthony James Hatswell
Nanxin Li
Koo Wilson
机构：
[1] Delta Hat,
[2] University College London,undefined
[3] Bioverativ,undefined
[4] a Sanofi Company,undefined
[5] Swedish Orphan Biovitrum AB (publ),undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：133 / 142
页数：9
相关论文
共 50 条
  • [31] Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a
    Konkle, Barbara
    Pasi, K. John
    Perry, David J.
    Mahlangu, Johnny
    Rangarajan, Savita
    Brown, Simon A.
    Hanabusa, Hideji
    Pabinger, Ingrid
    Cristiano, Lynda M.
    Tsao, Elisa
    Winding, Bent
    Glazebrook, Desilu
    Lethagen, Stefan
    Jackson, Shannon
    BLOOD, 2016, 128 (22)
  • [32] USE OF REAL-WORLD DATA IN COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS
    Singh, J.
    Stevenson, M. D.
    Hyrich, K.
    Gillies, C.
    Abrams, K.
    Bujkiewicz, S.
    VALUE IN HEALTH, 2022, 25 (12) : S373 - S374
  • [33] Use Of Real-World Data In Cost-effectiveness Analysis Of Sequential Biologic Treatment For Rheumatoid Arthritis
    Singh, Janharpreet
    Stevenson, Matt
    Hyrich, Kimme
    Gillies, Clare
    Abrams, Keith
    Bujkiewicz, Sylwia
    MEDICAL DECISION MAKING, 2024, 44 (02) : NP49 - NP50
  • [34] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B
    Powell, Jerry S.
    Perry, David
    Baker, Ross I.
    Shapiro, Amy
    Manco-Johnson, Marilyn J.
    Potts, James
    Robinson, Brian
    Mei, Baisong
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 94 - 94
  • [35] COST-EFFECTIVENESS ANALYSIS OF DIFFERENT RECOMBINANT FACTOR VIII FOR PROPHYLACTIC TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIAA IN CHINA
    Yang, L.
    Peng, J.
    Gu, C.
    Wang, Z.
    Zuo, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [36] Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Adults and Adolescents with Severe Haemophilia A: An Updated Interim Analysis of the Aspire Study
    Pasi, K. J.
    Perry, D. J.
    Mahlangu, J.
    Konkle, B. A.
    Rangarajan, S.
    Brown, S. A.
    Hanabusa, H.
    Jackson, S.
    Pabinger, I.
    Cristiano, L. M.
    Lethagen, S.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 64 - 65
  • [37] Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery
    Desage, Stephanie
    Nougier, Christophe
    Meunier, Sandrine
    Chamouard, Valerie
    Jousselme, Emilie
    Dargaud, Yesim
    Lienhart, Anne
    HAEMOPHILIA, 2024, 30 (02) : 538 - 544
  • [38] Real-world effectiveness and safety of a recombinant factor VIII Fc in patients with haemophilia A by disease severity: Pooled analysis (A-SURE/PREVENT)
    Holme, P. A.
    Alvarez Roman, M. T.
    Tagliaferri, A.
    Oldenburg, J.
    Halimeh, S.
    Lauer, S.
    Fusser, M.
    Gresko, E.
    Lethagen, S.
    HAEMOPHILIA, 2024, 30 : 83 - 83
  • [39] Second Interim Analysis of the Aspire Study Evaluating Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A
    Nolan, B.
    Young, G.
    Mahlangu, J.
    Liesner, R.
    Pasi, K. J.
    Lethagen, S.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 65 - 66
  • [40] Real-world effectiveness and safety of a recombinant factor VIII Fc in patients with haemophilia A by age groups: pooled analysis (A-SURE/PREVENT)
    Roman, M. T. Alvarez
    Oldenburg, J.
    Ettingshausen, C. Escuriola
    Lauer, S.
    Fusser, M.
    Gresko, E.
    Lethagen, S.
    HAEMOPHILIA, 2024, 30 : 77 - 77
12345